免疫重建荷人膀胱癌-SCID鼠模型的建立

目的：探讨建立稳定的荷人膀胱癌SCID 鼠人化复合模型的方法，为在人免疫重建荷人膀胱肿瘤SCID 鼠模型检测重组BCG 的免疫刺激和免疫保护中打下基础。方法：经SCID 鼠腹腔内注射人PBL、皮下接种RT4 膀胱癌细胞，于接种后4 周检测SCID 鼠体内人免疫细咆水平（IgG 和CD^3＋、CD^4＋、CD^8＋ T 细胞）及脾脏重量，观察皮下成瘤潜伏期及成瘤率。结果：模型组100％成瘤，病理类型为移行细胞癌；检测SCID 鼠血中人IgG 均一定水平存在，与对照组间差异有统计学意义（P〈0.01）；人CD^3＋、CD^4＋、CD^8＋T 细胞在鼠血及脾中均有表达，而对照组均未检出（P〈0.05）；4 周鼠脾重平均（178.9± 45.2）mg。较对照组（40.6± 14.8）mg 差异有统计学意义（P〈0.01）。结论：采用腹腔注射人PBL、皮下接种RT4膀胱癌细胞的方法可以有效地建立人化荷人膀胱癌SCID 鼠模型，较好地模拟人浸润性膀胱癌体内生物学特性，是膀胱癌免疫基因治疗的较理想模型。

Establishment and Identification of HU-PBL-SCID Mice Model of Human Bladder Cancer Model

Objective： To establish a human bladder cancer model in Hu-PBL-SCID mice. Methods： The immunological features of mice were evaluated after intra-peritoneal injection of hu-PBL and subcutaneous implantation of human RT4 cells. Results： 16 mice had pathologically transitional cell carcinoma tumor in group one. The level of the human 1N. Was gradually elevated in all the human- ized mice following the time of PBL transplantation prolonging until 4th week on, and was significantly higher than that in control mice （P〈0.01）. The different level of human CD^3＋, CD^4＋, CD^8＋ T cells among two groups was statistically significant（P〈0.05）. Furthermore, hu- man CD^3＋, CD^4＋, CDs＋ T cells in mice blood and spleen cells could be still detected at 4th week. The weight of spleen was averagely （178.9＋ 45.2） mg in group one at 4th week, and had statistical significance compared with the control group （P〈0.01）. Conclusion： Humanized SCID mice model can he successfully established via intraperitoneally human peripheral blood cells into SCID mice. The model simulated the real biological behavior of human bladder invasive carcinoma very well.